GINKGO BIOWORKS HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
GINKGO BIOWORKS HOLDINGS, INC. (DNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $900.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- GINKGO BIOWORKS HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-12-31 was $200.00K, a 71.43% decline year-over-year.
- GINKGO BIOWORKS HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was -$600.00K, a 110.91% decline year-over-year.
- GINKGO BIOWORKS HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-06-30 was -$2.60M, a 285.71% decline year-over-year.
- GINKGO BIOWORKS HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-03-31 was $3.90M, a 160.00% increase year-over-year.
- GINKGO BIOWORKS HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $900.00K, a 90.11% decline from fiscal 2023.
- GINKGO BIOWORKS HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $9.10M, a 57.67% decline from fiscal 2022.
- GINKGO BIOWORKS HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $21.50M, a 76.37% decline from fiscal 2021.
- GINKGO BIOWORKS HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $91.00M, a 1616.98% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$400.00K derived: sum of 2 quarters · filed 2026-02-26 | -$3.00M derived: sum of 3 quarters · filed 2026-02-26 | $900.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | -$600.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.20M derived: sum of 2 quarters · filed 2025-11-06 | $700.00K 10-Q · filed 2025-11-06 | $1.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.30M 10-Q · filed 2025-08-07 | $2.00M derived: sum of 3 quarters · filed 2026-02-26 | $7.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $3.90M 10-Q · filed 2025-05-06 | $4.60M derived: sum of 2 quarters · filed 2026-02-26 | $10.10M derived: sum of 3 quarters · filed 2026-02-26 | $11.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.20M derived: sum of 2 quarters · filed 2026-02-26 | $7.60M derived: sum of 3 quarters · filed 2026-02-26 | $9.10M 10-K · filed 2026-02-26 |
| 2023-09-30 | $5.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $6.90M derived: sum of 2 quarters · filed 2024-11-12 | $8.40M 10-Q · filed 2024-11-12 | $11.10M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.90M 10-Q · filed 2024-08-08 | $5.60M derived: sum of 3 quarters · filed 2025-02-25 | $15.30M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $1.50M 10-Q · filed 2024-05-09 | $4.20M derived: sum of 2 quarters · filed 2025-02-25 | $13.90M derived: sum of 3 quarters · filed 2025-02-25 | $7.70M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $12.40M derived: sum of 2 quarters · filed 2025-02-25 | $6.20M derived: sum of 3 quarters · filed 2025-02-25 | $21.50M 10-K · filed 2025-02-25 |
| 2022-09-30 | $9.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $3.50M derived: sum of 2 quarters · filed 2023-11-08 | $18.80M 10-Q · filed 2023-11-08 | $60.90M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$6.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $9.10M 10-Q · filed 2023-08-09 | $51.20M derived: sum of 3 quarters · filed 2024-02-29 | $79.80M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $15.30M 10-Q · filed 2023-05-10 | $57.40M derived: sum of 2 quarters · filed 2024-02-29 | $86.00M derived: sum of 3 quarters · filed 2024-02-29 | $94.90M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $42.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $70.70M derived: sum of 2 quarters · filed 2024-02-29 | $79.60M derived: sum of 3 quarters · filed 2024-02-29 | $91.00M 10-K · filed 2024-02-29 |
| 2021-09-30 | $28.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $37.50M derived: sum of 2 quarters · filed 2022-11-14 | $48.90M 10-Q · filed 2022-11-14 | $39.10M derived: sum of 4 quarters · filed 2023-03-13 |
| 2021-06-30 | $8.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $20.30M 10-Q · filed 2022-08-15 | $10.50M derived: sum of 3 quarters · filed 2023-03-13 | |
| 2021-03-31 | $11.40M 10-Q · filed 2022-05-16 | $1.60M derived: sum of 2 quarters · filed 2023-03-13 | ||
| 2020-12-31 | -$9.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $5.30M 10-K · filed 2023-03-13 | ||
| 2020-09-30 | $15.10M 10-Q · filed 2021-11-15 | |||
| 2019-12-31 | $1.10M 10-K · filed 2022-03-29 |